Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.48 |
| ▸ | CA1 | P00915 | 12/20 | 0.48 |
| ▸ | CA9 | Q16790 | 9/20 | 0.48 |
| ▸ | CA12 | O43570 | 8/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 4/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA6 | P23280 | 3/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156731 | 0.82 | PAX8 (0.38) | CA2CA1CA9 | |
| SCHEMBL309805 | 0.82 | TSHR (0.37) | CA2CA1CA9CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL7416278 | 0.80 | PAX8 (0.36) | CA2CA1CA9 | |
| SCHEMBL10369537 | 0.73 | CA2 (0.47) | CA2CA1CA9CA12CA4 | |
| SCHEMBL10467411 | 0.72 | CA1 (0.42) | CA2CA1CYP2C9 | |
| SCHEMBL8798918 | 0.72 | MTNR1A (0.35) | CA2CA1CYP2C9 | |
| SCHEMBL276253 | 0.69 | ALDH1A1 (0.39) | LMNACYP2C9 | |
| SCHEMBL2008190 | 0.69 | ALDH1A1 (0.42) | RAB9A | |
| SCHEMBL13261664 | 0.67 | ALDH1A1 (0.43) | RAB9A | |
| SCHEMBL17394560 | 0.67 | ALDH1A1 (0.38) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514556-B2 | Inhibitors of β-lactamase | METHYLGENE INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | METHYLGENE, INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-7259172-B2 | phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance | METHYLGENE INC. (CA) | 2007-08-21 | — | — | US | disclosed |
| US-20060105999-A1 | Novel inhibitors of beta-lactamase | METHYLGENE, INC. (CA) | 2006-05-18 | — | — | US | disclosed |
| US-7030103-B2 | Sulfonamidomethyl phosphonate inhibitors of β-lactamase | METHYLGENE, INC. (CA) | 2006-04-18 | — | — | US | disclosed |
| EP-1194436-B1 | SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE | METHYLGENE INC (CA) | 2005-11-30 | — | — | EP | disclosed |
| US-6921756-B2 | Inhibitors of β-lactamase | METHYLGENE, INC. (CA) | 2005-07-26 | — | — | US | disclosed |
| US-6884791-B2 | Inhibitors of β-lactamase | METHYLGENE, INC. (CA) | 2005-04-26 | — | — | US | disclosed |
| US-20050043276-A1 | Novel inhibitors of beta-lactamase | METHYLGENE, INC. (CA) | 2005-02-24 | — | — | US | disclosed |
| WO-2004048393-A2 | NOVEL INHIBITORS OF β-LACTAMASE | METHYLGENE, INC. (CA) | 2004-06-10 | — | — | WO | disclosed |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | METHYLGENE, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040059115-A1 | Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase | 92229129 QUEBEC INC. (CA) | 2004-03-25 | — | — | US | disclosed |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | 92229129 QUEBEC INC. (CA) | 2004-02-12 | — | — | US | disclosed |
| US-6472406-B1 | Sulfonamidomethyl phosphonate inhibitors of beta-lactamase | METHYLGENE, INC. (CA) | 2002-10-29 | — | — | US | disclosed |
| EP-1194436-A1 | SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE | Methylgene, Inc. (CA) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001002411-A1 | SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE | METHYLGENE INC. (CA) | 2001-01-11 | — | — | WO | disclosed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043276-A1 | Novel inhibitors of beta-lactamase | MGAM, LSS, CYP51A1 | CA2 2716/4885CA1 4384/4885CA9 1091/4885 |
| US-20040029836-A1 | Novel inhibitors of beta-lactamase | LSS, MGAM, COASY | CA2 2629/4885CA1 4178/4885CA9 964/4885 |
| US-20060105999-A1 | Novel inhibitors of beta-lactamase | LSS, MGAM, LCT | CA2 2457/4885CA1 4321/4885CA9 1062/4885 |
| US-20040059115-A1 | Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase | PGLS, MGAM, STS | CA2 2859/4885CA1 4176/4885CA9 1737/4885 |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | MGAM, LSS, CYP51A1 | CA2 2716/4885CA1 4384/4885CA9 1091/4885 |
| US-20040082546-A1 | Novel Inhibitors of beta-lactamase | LSS, MGAM, COASY | CA2 2498/4885CA1 4194/4885CA9 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.